

1 **TITLE PAGE**

2

3 **Title:** COVID MED – An Early Pandemic Trial of Losartan for Hospitalized
4 COVID-19 Patients

5 **Authors/Affiliations:** Daniel Freilich, MD, Bassett Medical Center (Cooperstown, NY, USA),
6 daniel.freilich@bassett.org

7 Jennifer Victory, RN, BS, Bassett Research Institute (Cooperstown, NY,
8 USA), jennifer.victory@bassett.org

9 Paul Jenkins, PhD, Bassett Research Institute (Cooperstown, NY, USA),
10 paul.jenkins@bassett.org

11 James Wheeler, MD, Goshen Health (Goshen, IN, USA),
12 jwheeler@goshenhealth.com

13 G. Matthew Vail, MD, Reid Health (Richmond, IN, USA),
14 matthew.vail@reidhealth.org

15 Erik Riesenfeld, MD, Bassett Medical Center (Cooperstown, NY, USA),
16 erik.riesenfeld@bassett.org

17 Peggy Cross, Bassett Research Institute (Cooperstown, NY, USA),
18 peggy.cross@bassett.org

19 Catherine Gilmore, RN, Bassett Research Institute (Cooperstown, NY,
20 USA), catherine.gilmore@bassett.org

21 Melissa Huckabone, RN, Bassett Research Institute (Cooperstown, NY,
22 USA), melissa.huckabone@bassett.org

23 Anna Schworm, RN, Bassett Research Institute (Cooperstown, NY,
24 USA), annaschworm@gmail.com

25 Umesha Boregowda, MD, Bassett Medical Center (Cooperstown, NY,
26 USA), umesha.boregowda@bassett.org

27 Farah Deshmukh, MD, Bassett Medical Center (Cooperstown, NY,
28 USA), farah.deshmukh@gmail.com

29 Yuri Choi, MD, Bassett Medical Center (Cooperstown, NY, USA),
30 yuri.choi@bassett.org

31 Azkia Khan, MD, Bassett Medical Center (Cooperstown, NY, USA),
32 azkia.kahn@bassett.org

33 Anne Gadomski, MD, MPH, Bassett Research Institute (Cooperstown,
34 NY, USA), anne.gadomski@bassett.org

35 **Corresponding Author:** Daniel Freilich, MD, Bassett Medical Center, 1 Atwell Rd, Cooperstown,
36 NY 13326 (USA). daniel.freilich@bassett.org

37 **Authors' contributions:** DF conceived of the study. DF, JV, and AG initiated the study design
38 and DF, JV, JW, GMV, ER, PC, CG, MH, AS, UB, FD, YC, AK, and
39 AG helped with implementation.

40 FD, YC, and AK are grant holders.

41 PJ provided statistical expertise in clinical trial design and in conducting
42 the primary statistical analysis.

43 All authors contributed to refinement of the study protocol and approved
44 the final manuscript.

45 **DOI Statement:** None of the authors have any competing/conflicting interests to declare

46 **Authorship Role:** All authors collaborated in the writing/editing of the manuscript

47 **Article Type:** Original article – RCT

48 **Running Head:** Losartan for COVID-19

49

50 **ABSTRACT**

51 *Background*

52 ACEi/ARB medications have been hypothesized to have potential benefit in COVID-19. Despite concern
53 for increased ACE-2 expression in some animal models, preclinical and observational-retrospective and
54 uncontrolled trials suggested possible benefit. Two RCTs of the ARB losartan from University of
55 Minnesota showed no benefit yet safety signals for losartan in outpatient and hospitalized COVID-19
56 patients. COVID MED, started early in the pandemic, also assessed losartan in a RCT in hospitalized
57 patients with COVID-19.

58 *Methods*

59 COVID MED was quadruple-blinded, placebo-controlled, multicenter randomized clinical trial (RCT).
60 Hospitalized COVID-19 patients were randomized to receive standard care and hydroxychloroquine,
61 lopinavir/ritonavir, losartan, or placebo. Hydroxychloroquine and lopinavir/ritonavir arms were
62 discontinued after RCTs showed no benefit. We report data from the losartan arm compared to combined
63 (lopinavir-ritonavir and placebo) and prespecified placebo-only controls. The primary endpoint was the
64 NCOSS slope of change. Slow enrollment prompted early stopping.

65
66 *Results*

67 Of 432 screened patients, 14 were enrolled (3.5%), 9 received losartan and 5 combined control
68 (lopinavir/ritonavir [N=2], placebo [N=3]); 1 hydroxychloroquine arm patient was excluded. Most
69 baseline parameters were balanced. Treatment with losartan was not associated with a difference in
70 NCOSS slope of change in comparison with combined control ($p=0.4$) or placebo-only control ($p=0.05$)
71 (trend favoring placebo). 60-day mortality and overall AE and SAE rates were numerically but not
72 significantly higher with losartan.

73 *Conclusions*

74 In this small blinded RCT in hospitalized COVID-19 patients, losartan did not improve outcome vs.
75 control comparisons and was associated with adverse safety signals.

76
77
78 *Keywords*

79 Losartan, angiotensin converting enzyme inhibitor (ACEi), angiotensin II receptor blocker (ARB),
80 COVID-19, SARS-CoV-2, randomized clinical trial (RCT)

81

82 INTRODUCTION

83 Angiotensin converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) have been
84 hypothesized to have benefit in COVID-19 secondary to inhibition of pneumocyte ACE-2 receptors
85 resulting in decreased SARS-CoV-2 entry, as well as local vasodilation/vasoconstriction alteration and
86 anti-inflammatory effects. Animal studies suggested potential for benefit. Safety concerns have included
87 observations of increased ACE-2 receptor expression in some animal models and potential for medication
88 class adverse events (e.g., acute kidney injury [AKI]). Retrospective and observational continuation-
89 discontinuation trials [1-10], open-label interventional trials [11-15], and a meta-analysis [16] showed
90 trends favoring benefit. Two blinded RCTs, however, showed no benefit yet adverse safety signals [17-
91 18]. We initiated the COVID MED trial at the pandemic onset prior to publication of ACEi/ARB
92 COVID-19 clinical trials, aiming to assess the ARB losartan (and hydroxychloroquine and
93 lopinavir/ritonavir) in hospitalized COVID-19 patients.

94

95 MATERIALS AND METHODS

96 COVID MED (NCT04340557) was approved by the Institutional Review Boards of Bassett Medical
97 Center (Cooperstown, NY [April 3, 2020] [#1581969]), Goshen Health (Goshen, IN) and Reid Health
98 (Richmond, IN). Initiated at the pandemic onset, we could not project COVID-19 admission numbers,
99 thus, an arbitrary N of 4,000 hospitalized patients with laboratory-confirmed SARS-CoV-2 (screening
100 criteria) was selected with prespecification for sample size/power calculations and updating after interim
101 analysis. Our primary objective was to assess whether treatment with hydroxychloroquine,
102 lopinavir/ritonavir, or losartan, would result in more rapid improvement in the 7-point NIAID COVID-19
103 Ordinal Scale Score (NCOSS) in comparison with placebo. NCOSS is as follows: 1) Death; 2)
104 Hospitalized, on mechanical ventilation or ECMO; 3) Hospitalized, on NIV/high flow oxygen; 4)
105 Hospitalized, requiring oxygen; 5) Hospitalized, not requiring oxygen; 6) Not hospitalized, with
106 limitations; 7) Not hospitalized, without limitations. Enrolled patients were followed for up to 60 days.

107 Target recruitment was maximized by daily assessment of positive SARS-CoV-2 swab tests from
108 Bassett's laboratory in hospitalized patients with review of inclusion/exclusion criteria for all such
109 patients by the study's enrollment nurse and offering enrollment to all interested in participating after a
110 comprehensive informed consent process (see Supplementary material for Informed Consent Form
111 [ICF]). Post-consent, patients were randomly assigned by an unblinded enrollment research nurse in a
112 2:2:2:1 ratio in blocks to one of four groups using a computer-generated randomization schedule provided
113 by the study's statistician (without stratification): hydroxychloroquine, lopinavir/ritonavir, losartan, or

114 placebo; this ratio was selected because early in the pandemic patients declined participation in trials with
115 low likelihood of receiving ‘active’ drug. Allocation concealment was ensured by having only the
116 enrollment research nurse be unblinded and with maintaining confidentiality of the allocation.

117 All groups received standard care, which transformed over time. Hydroxychloroquine and
118 lopinavir/ritonavir enrollment were halted after other RCTs showed no benefit [19-20]; a 2:1 ratio
119 computer-generated randomization schedule for losartan and placebo was used thereafter. Herein, we
120 focus on the trial design and results for losartan vs. combined control groups (we included 2
121 lopinavir/ritonavir patients as other RCTs showed no benefit or safety concerns [20]. We also report ITT
122 data for the comparison of the losartan and placebo-only group, per our prespecified statistical analysis
123 plan (SAP). Low enrollment led to study termination (July 2021).

124 Inclusion criteria were (1) hospitalized; (2) >18 years-old; (3) laboratory-confirmed SARS-CoV-2
125 infection; (4) randomization within 72 hours of admission; and (5) able to provide consent. General
126 exclusion criteria applicable to all groups included (1) ESRD; (2) severe hepatic insufficiency; (3)
127 nausea/vomiting/aspiration risk precluding oral medications unless can be given by nasogastric tube; (4)
128 use of another SARS-CoV-2 medication; (5) pregnancy/breast feeding; (6) no contraception; and (7)
129 inability to obtain consent. Each treatment group had specific exclusions based on the medication’s
130 safety profile. Specific losartan group exclusion criteria included (1) ARB allergy/intolerance; (2) taking
131 ACEi/ARB; (3) hypotension; (4) hyperkalemia; (4) severe renal dysfunction; (5) severe volume
132 depletion/AKI; (6) ascites; (7) aortic/mitral stenosis; (8) renal artery stenosis; and (9) co-administration of
133 CYP3A interacting drugs. Minor modifications were made during the study. There were no placebo group
134 specific exclusion criteria. After hydroxychloroquine and lopinavir-ritonavir enrollment was stopped,
135 inclusion/exclusion criteria were the same for the losartan and placebo groups.

136 Study drug (losartan or TicTacs placebo [lopinavir-ritonavir in 2 patients]) was prepared by a pharmacist
137 who inserted the ‘pills’ into blank capsules – enabling cost-effective quadruple-blinding (patient, clinical
138 nurse/physician, study nurse, investigators); only the enrollment study nurse was unblinded but he/she
139 had no other responsibilities after enrollment. Unblinding was not done. If crushed drug or drug in
140 solution had to be administered (nasogastric/gastric tube), eye shields were used to maintain blinding.
141 Dosing was initially twice daily in all groups to mask varying regimens (losartan group: losartan and
142 placebo; placebo group: placebo and placebo; lopinavir/ritonavir group: lopinavir/ritonavir twice daily).
143 The losartan dose was 25 mg; the lopinavir/ritonavir dose was 400/100 mg. After hydroxychloroquine
144 and lopinavir/ritonavir groups enrollment ceased, losartan and placebo dosing were daily. Dosing duration
145 target was 14 days (minimum 5 days) if tolerated (no clinically relevant related AEs/SAEs such as
146 hypotension, hyperkalemia, or worsening renal function). Adherence to study dosing was monitored and

147 noted by the study's research nurse. Patients discharged early were administered a shorter 5-day course
148 with a minimum of 1.5 days as an in-patient (3 doses) and 3.5 days as an out-patient (7 doses).

149 With the initial study plan to recruit up to 4,000 subjects, the 2:2:2:1 assignment was predicted to result in
150 571 subjects in the placebo group and 1,143 subjects in each treatment group. An independent, conflict-
151 free, and multidisciplinary Data Monitoring Committee (DMC) was convened at the study's outset and
152 agreed to its processes and goals; unexpected SAE reports were shared with the DMC. Interim analysis
153 was planned for each treatment group at an information fraction of 0.1, which would occur when a
154 treatment group had slopes for 114 subjects, and the control group has slopes for 57. After
155 hydroxychloroquine and lopinavir/ritonavir were dropped, we planned interim analysis and sample size
156 optimization upon enrollment of 114 losartan and 57 placebo subjects. However, the study was stopped
157 due to slow enrollment prior to the first planned DMC interim analysis.

158 Protocol CRFs were used to collect standardized efficacy/safety data; telephone follow-up was used as
159 much as possible after discharge to obtain planned efficacy/safety data but inability to meet participants
160 due to COVID-19 safety restrictions precluded complete data collection. Additional blood tests for more
161 extensive safety monitoring were completed for patients who consented. AEs were classified in
162 accordance with NCICTC for Adverse Events, version 4.0 (standard grading procedures). COVID MED
163 was carried out in accordance with principles of the Code of Ethics of the World Medical
164 Association (Declaration of Helsinki) and GCP guidelines of the International Conference on
165 Harmonization, with general principles of protection of humans participating in research. Data from CRFs
166 and AE/SAE reports were entered into REDCap using secure login/password entry; data were
167 deidentified in working documents which were available only to study investigators; all study identifying
168 data will be destroyed/deleted upon publication to allow wider sharing if requested.

169

170 *Statistical Analysis*

171 As per our prespecified SAP, subjects had NCOSS values recorded for up to 11 timepoints (days 0, 1-7,
172 14, 30, and 60). These 11 X (time) Y (NCOSS) pairs were be used to calculate the slope of the change in
173 NCOSS values over time for each subject. Only X-Y pairs up to and including the first attainment of
174 NCOSS level 7 were included. These slopes of the change in NCOSS levels over time served as the
175 primary endpoint for each subject.

176 The study design was such that it constituted three unique trials, all of which utilized the same control
177 (placebo) group. Means of the slopes for each of the three different treatments were compared separately
178 to mean slope in the control group using Student's t-test. We report methods/results for comparison of the

179 losartan vs. placebo-only arms per the prespecified SAP, but also, because of our small N, post-hoc
180 comparison with combined controls (lopinavir/ritonavir and placebo).

181 Continuous and categorical secondary endpoints were compared using Student's t-test and Fisher's exact
182 test, respectively. Secondary analyses included but were not limited to hospital LOS, mechanical
183 ventilation duration, and 60-day mortality. Time to resolution of nasopharyngeal viral shedding (PCR)
184 was compared. For safety, the primary outcome was the intention-to-treat (ITT) 60-day overall SAE rate;
185 secondary measurements included overall AE rates, and AKI, hypotension, and hyperkalemia AE/SAE
186 rates. Adjusted and subgroups analyses were not done due to small sample size. For the primary outcome,
187 missing values were addressed with conventional last-observation-carried-forward (LOCF).

188

189 **RESULTS**

190 *Screening/enrollment*

191 Of 432 screened patients, 14 were enrolled (3.5%), 9 receiving losartan and 5 receiving control
192 (placebo=3, lopinavir/ritonavir=2); 1 hydroxychloroquine arm patient was not included herein. Reasons
193 for non-inclusion at Bassett: patient declined (12.0%), taking ACEi/ARB (26.9%), outside enrollment
194 window (20.1%), hypotension (1.6%), hyperkalemia (2.1%), renal disease (4.2%), altered mental status
195 precluding consent (11.6%), hospitalized for non-COVID-19 reasons (asymptomatic) (10.4%), and other
196 (11.1%).

197

198 *Baseline parameters/demographics*

199 Comparisons of losartan and combined control baseline data revealed balanced parameters other than
200 comorbidities. Specifically, mean age was 63.7 vs. 61.8 years, and males accounted for 66.7% vs. 60%,
201 respectively. 100% were Caucasian and 100% were ward patients in both groups. Mean NCOSS was 3.6
202 vs. 4.0, (p=0.5), qSOFA 0.33 and 0.6 (p=0.4), and creatinine 0.7 vs. 0.9 (p=0.4), respectively. Chest x-ray
203 opacities consistent with pneumonia were seen in 88.9 vs. 100% (p=0.9). PSI scores were similar – 54.9
204 and 59.3 (p=0.5). Mean BMI was 31.0 and 31.8 (p=0.4). The mean targeted comorbidities rate (per
205 subject) was lower with losartan than combined control (1 vs. 2.6, p=0.02); a similar trend was seen for
206 the Charlson Score (2.5 vs. 4.5, p=0.08). Treatment occurred at a median of 9.3 vs. 7.4 days after
207 symptoms onset (p=0.3). Treatment duration mean was 9.6 vs. 13.3 days, respectively (p=0.3). 88.9 vs.
208 50% of patients received corticosteroids (p=0.5). Most patients were enrolled between the spring of 2020
209 and the winter of 2021 (88.9 vs. 80%). Baseline comparisons for losartan vs. placebo-only control were
210 similar (see Table 1).

211

212 *Efficacy*

213 NCOSS data were recorded for 97% of losartan group timepoints (3% missingness), 94.5% of combined
214 control (lopinavir/ritonavir and placebo) group timepoints, and 100% of placebo-only control group
215 timepoints. The slopes of the change for NCOSS were 0.00365 for losartan ($p=0.5$), 0.02091 for
216 combined control ($p=0.07$), and 0.05268 for placebo-only control ($p=0.002$). Comparisons of the slopes
217 of the change for NCOSS, our primary outcome measurement, revealed: losartan vs. combined control
218 ($p=0.4$), losartan vs. placebo-only control ($p=0.05$) (trend favoring placebo), combined control vs.
219 placebo-only control ($p=0.267$) (see Figure 1).

220

221 Mean NCOSS change at 60 days was numerically but not significantly lower with losartan (0.7) than
222 combined control (1.8) ($p=0.6$). Mortality at 60 days (44.4 vs. 20%, $p=0.9$), mean LOS (16.4 vs. 7.0 days,
223 $p=0.2$), and mean mechanical ventilation duration (8.5 vs. 0 days) were worse with losartan but also not
224 significantly (see Table 2).

225

226 *Safety*

227 The primary safety outcome measurement, the overall SAE rate (per subject), was numerically higher
228 with losartan vs. combined control (2.0 vs. 0.6%) and vs. the placebo-only control (2.0 vs. 0%). The
229 overall AE rate (per subject) trend was similar, being higher with losartan than combined control (3.9 vs.
230 1.0%) and vs. placebo-only control (3.9 vs. 0%). AKI AE and SAE rates were similar, but hypotension
231 and hyperkalemia, as well as respiratory failure AE and SAE rates, were numerically higher with losartan
232 than combined control and placebo-only control. No safety comparison was statistically significantly
233 different (see Table 3).

234

235 Planned subgroups analysis and adjustment for baseline parameters was not done due to the small N of
236 the enrolled population.

237

238 **DISCUSSION**

239 COVID MED, to our knowledge, the third blinded, placebo-controlled RCT assessing an ARB in
240 COVID-19, did not find significant group differences in the NCOSS score for hospitalized patients
241 treated with losartan vs. control. A statistically insignificant trend favoring control was found for our
242 prespecified primary efficacy outcome measurement, the ITT comparison of the NCOSS slope of the
243 change vs. placebo-only control ($p=0.05$). Our primary safety outcome measurement, overall SAE rate,
244 was numerically but not statistically significantly higher with losartan. Secondary outcomes also

245 numerically favored placebo but no group comparisons were statistically significantly different –
246 including mortality.

247 Although COVID MED was small and pilot-like in scope, its results are value-added in that they add
248 randomized, blinded, and placebo-controlled data to the limited ACEi/ARB literature in COVID-19. Our
249 results are similar to those found in two larger blinded RCTs [17-18]; these three RCTs do not support
250 empiric starting of ACEi/ARB, at least ARB, in COVID-19 outside of RCTs. Given the negative results
251 of these blinded studies, it is worth reviewing the evidence for ACEi/ARB in COVID-19.

252 *Preclinical data*

253 SARS-CoV and SARS-CoV-2 viruses enter cells by binding to cellular ACE2 receptors which are
254 expressed on lung type II pneumocytes, enterocytes, kidney, and vascular cells [21-26]. Animal viral
255 pneumonia models provided indirect support showing improved outcome with losartan, including
256 amelioration of lung injury, edema, and lung failure in a SARS-CoV infection model [26], and of lung
257 injury, edema, and leukocyte infiltration in an influenza A H5N1 mouse model [27].

258 Some researchers raised concern early in the pandemic that ACEi/ARB might worsen COVID-19
259 outcome [28-29] because in some (not all) animal models, ACE2 expression may be upregulated by these
260 drugs potentially increasing virus cell injury [30-37]. Human studies do not show increased plasma ACE2
261 levels with ACEi/ARB [38-40]. ARB have been hypothesized to stabilize with the ATR-1-ACE2
262 complex causing AT-1,7 generation leading to vasodilation and diminished inflammation [41]. These
263 effects may be more important than ACE-2 inhibition/viral entry inhibition.

264 In sum, animal studies have shown potential for benefit with ACEi/ARB in viral pneumonias and
265 inconsistent data suggesting potentially adverse increased ACE-2 expression.

266 *Retrospective/observational clinical trials*

267 A Chinese retrospective study compared mortality in hypertensive hospitalized COVID-19 patients who
268 were taking ACEi/ARB or were not [1]. Unadjusted and adjusted mortality was lower with ACEi/ARB.
269 In another Chinese retrospective study in hypertensive hospitalized COVID-19 patients, progression to
270 severe disease/mortality was similar in those taking vs. not taking ACEi/ARB [2]. An observational
271 database of international hospitalized COVID-19 patients showed similar in-hospital mortality for
272 ACEi/ARB use [3]. A NYU database review found no association for ACEi/ARB use and COVID-19 or
273 severe COVID-19 [4]. An Italian case-control study found no association for ACEi/ARB use and
274 COVID-19 [5].

275 In another hospitalized COVID-19 patient cohort, adjusted death/ICU transfer occurred less frequently
276 with ACEi vs. non-ACEi use [6]. Danish national registry retrospective cohort and case-control studies
277 found no significant associations for mortality and composite mortality/severe COVID-19 in patients
278 taking vs. not taking ACEi/ARB [7]. An observational trial evaluating hydroxychloroquine/chloroquine
279 found baseline ACEi (but not ARB) use to be associated with decreased mortality [3]. A Cleveland Clinic
280 Health System retrospective cohort study reported no association for ACEi/ARB use and COVID-19 [8].
281 In a retrospective Stanford study of COVID-19 inpatients/outpatients, ACEi/ARB use was not associated
282 with higher hospitalization, ICU risk, or death; hospitalization was lower [9].

283 In sum, these retrospective studies showed no safety signals for ACEi or ARB in COVID-19 [10] and
284 possible benefit in some, supporting RCTs.

285 *Retrospective/observational clinical trials in influenza*

286 A query of UK's Clinical Practice Research Datalink showed lower influenza rates with ACEi/ARB use
287 vs. non-use [42]. Influenza A relies on the ACE2 receptor for lung entry, like SARS-CoV-2.

288 *Prospective clinical trials*

289 The BRACE CORONA trial compared discontinuation vs. continuation of ACEi/ARB already taken by
290 659 mild-moderate hospitalized COVID-19 patients in Brazil [11]. Median time from symptoms onset
291 was 6 days. The trial found no differences in the primary outcome of days alive outside the hospital at day
292 30 (mean, 21.9 vs. 22.9 days). No significant differences in mortality and AEs were seen.

293 A second similar discontinuation vs. continuation trial of ARB already taken by 152 hospitalized COVID-
294 19 patients was also published (REPLACE COVID) [12]. Median time from symptoms onset was 6.5-6.8
295 days. There was no difference in the study's primary outcome, a global rank score including time-to-
296 death, mechanical ventilation time, renal replacement, vasopressor time, and MOF. Mortality (13 vs.
297 15%), ICU admission/mechanical ventilation (18 vs. 21%), and AEs (36 vs. 39%) did not differ.

298 We are aware of five published ACEi/ACE in COVID-19 intervention trials (four inpatient, one
299 outpatient).

300 The first, from University of Kansas, was a single-arm open-label trial assessing the ARB losartan in
301 hospitalized COVID-19 patients requiring oxygen [13]. Thirty active treatment patients vs. 30 post-hoc
302 external controls using propensity scores were compared, with the primary outcome being AE incidence.
303 AE incidence (80 vs. 97%) and AE rates were lower with losartan (2.2 vs. 3.3); Poisson regression
304 adjusted AE incidence ratio remained lower with losartan (0.69; 95% CI: 0.49-0.97); elevated creatinine
305 AEs occurred in 30 vs. 23%, and elevated AST in 33 vs. 63%. No significant differences were found for

306 death (1/30 vs. 3/30) or mechanical ventilation (2/17 vs. 5/17) (trends favored losartan); hospital and ICU
307 LOS and days requiring oxygen or mechanical ventilation were similar. Study limitations included single-
308 arm, nonrandomized, open-label design with external historical controls, and between-group imbalance.
309 34 of 347 screened patients were enrolled (10%).

310 The second, an open-label RCT compared the ARB telmisartan and SOC vs. SOC alone in two
311 hospitalized COVID-19 patients in Argentina up to 4 days post symptoms onset (earlier than our trial)
312 [14]. The primary outcome was CRP at days 5 and 8. In an interim analysis, 40 telmisartan/SOC vs. 38
313 SOC were compared. Mean CRP was significantly lower in telmisartan/SOC vs. SOC groups at days 5
314 (24.2 vs. 51.1 mg/L [$p<0.05$]) and 8 (9.0 vs. 41.6 mg/L [$p<0.05$]). Median time to discharge was shorter
315 with telmisartan, 9 vs. 15 days ($p=0.01$) and 30-day mortality trend favored telmisartan (5.26 vs. 11.76%,
316 $p=0.41$); there were no differences for ICU admission, mechanical ventilation, and a composite of ICU
317 admission, mechanical ventilation, and death; fewer patients receiving telmisartan needed oxygen at day
318 15 (2/4 vs. 13/14, $p<0.05$). No telmisartan related AEs occurred and BP was similar. 82 of 185 screened
319 patients were enrolled (56% [higher than our trial]).

320 The third, an open-label RCT compared the ARB losartan and SOC vs. SOC alone in 31 SHARP (San
321 Diego) hospitalized patients with COVID-19 with mild hypoxia (requiring ≤ 3 L oxygen) [15]. The
322 primary measurement was a composite of mechanical ventilation/death. No significant primary or
323 secondary differences were found: the composite endpoint occurred in 1/16 vs. 1/15 losartan/SOC vs.
324 SOC patients; mortality occurred in 1/16 vs. 1/15 patients; mean LOS was 9 vs. 10 days; hypotension
325 occurred in 3/16 vs. 4/15. O₂ requirements were similar.

326 The fourth, the first blinded placebo-controlled RCT, compared losartan to placebo in outpatients with
327 mild COVID-19 conducted by University of Minnesota [17]. Of 117 enrolled patients, hospitalization
328 (primary outcome) occurred in 3/58 (5.2%) vs. 1/59 (1.7%) of losartan vs. placebo patients – an
329 insignificant absolute difference of -3.5% favoring placebo (95% CI -13.2, 4.8%; $p=0.320$). ICU
330 admissions and viral loads were similar; there were no deaths. The rate of NCOSS <5 at day 15 was 7/55
331 (12.7%) with losartan and 2/54 (3.6%) with placebo, with an adjusted OR (age and gender) of -1.4 (95%
332 CI -3.4, 0.2; $p = 0.096$), favoring placebo. AE rates were similar, 0.33 vs. 0.37, respectively; SAE rates
333 were similar. No significant AKI, hypotension, or hyperkalemia occurred. This RCT was terminated early
334 due to futility due low rates of events. 117 of 14,371 screened patients were enrolled (0.81%); 89.8% did
335 not meet inclusion/exclusion criteria.

336 The fifth, also by University of Minnesota, was the second randomized placebo-controlled RCT,
337 comparing losartan (N=101) and placebo (N=104) in hospitalized COVID-19 patients [18]. Losartan

338 dosing was 50 mg twice daily for 10 days (higher than in our study). The primary outcome, the
339 PaO₂/FiO₂ ratio at 7 days was similar [difference -24.8 (95% CI, -55.6 to 6.1; p=0.12)]. There were no
340 differences in secondary outcomes including 90-day mortality (10.9 vs. 10.6%, respectively), LOS,
341 oxygen and mechanical ventilation requirement at 10 days, or NCOSS. More losartan vs. placebo patients
342 needed vasopressors (20 vs. 11%, p=0.08) and vasopressor-free days were lower with losartan (8.7 vs.
343 9.4, p=0.04); our study found numerically higher hypotension AE/SAE rates analogously. Overall AE and
344 SAE rates were numerically higher with losartan (not significant); AKIs were more common with losartan
345 (19.4 vs. 8.8%, p=0.04). This trial's design and applicability was most like ours, including low
346 enrollment:screening (5%). Notable differences include larger N, higher dosing, and lower mortality;
347 similarities include lack of efficacy findings accompanied by numerically higher safety signals with
348 losartan.

349 In sum, the ACEi/ARB continuation:discontinuation trials and small unblinded treatment trials in
350 hospitalized COVID-19 patients showed equivalent or improved outcome. In contrast, both blinded RCTs
351 showed lack of efficacy and adverse safety signals [17-18].

352 *Meta-analyses*

353 A recent ACEi/ARB COVID-19 continuation:discontinuation meta-analysis (52 studies – 101,949
354 patients, 26,545 ACEi/ARB) found lower adjusted mortality and SAE rates with ACEi/ARB use [16].

355 Two pooled analyses of ACEi/ARB in COVID-19 are currently being completed and results should be
356 forthcoming: (1) an IPD-based analysis of North American trials in hospitalized COVID-19 patients; (2) a
357 larger aggregate data-based international meta-analysis by the International Society of Hypertension of
358 outpatient and hospitalized COVID-19 patients [43]. COVID MED data are included in both.

359 *Guidelines, professional societies, and reviews*

360 NIH guidelines, professional societies, and reviews recommend that ACEi/ARB, if already taken, should
361 be continued but not started anew outside RCTs [10, 29-30, 44-49].

362 *Study strengths and limitations*

363 The strengths of our study include its design (randomized, controlled, blinded), minimal primary outcome
364 measurements missingness, and baseline balance. Limitations include small N, early termination,
365 inclusion of lopinavir/ritonavir in post-hoc combined control comparisons, and low enrollment rate
366 making conclusions relevant to a small proportion of hospitalized COVID-19 patients.

367 *Conclusions*

368 Our blinded and controlled RCT comparing losartan and control in hospitalized COVID-19 patients found
369 no significant efficacy effect (NCOSS or mortality) which is not surprising given its small size, yet it
370 found potential safety signals. We speculate that class adverse effects of ACEi/ARB may overcome
371 theorized SARS-CoV-2-ACE-2 binding inhibition and other potential benefits making the overall benefit
372 to risk ratio for these medications in COVID-19 null or negative. Given that results from our blinded RCT
373 simulate those of the other two larger blinded RCTs to date, in effect a small third ‘negative’ RCT, unless
374 forthcoming pooled analyses find conflicting results, ARBs should not be started *de novo* to treat
375 COVID-19 outside of clinical trials.

376

377 *Acknowledgements*

378 We thank our study patients for participating in this RCT during the difficult times of the COVID-19
379 pandemic. We thank Jessica Kumar, MD, and Elizabeth Dufort, MD, and colleagues at New York State
380 Department of Health, Albany, NY, for assistance with nasopharyngeal PCR processing and study drug
381 supply.

382 *Funding*

383 This work was supported by a Bassett Research Institute ED Thomas Grant and salary support from the
384 Bassett Research Institute and Bassett Medical Center’s Department of Internal Medicine.

385

386

387

388

389 **REFERENCES**

- 390 1. Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J, et al. Association of Inpatient Use of Angiotensin
391 Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients
392 With Hypertension Hospitalized with COVID-19. *Circulation Research* 2020;**126**:1671–1681.
- 393 2. Li J, Wang X, Chen J, Zhang H, Deng D. Association of Renin-Angiotensin System Inhibitors With
394 Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019
395 (COVID-19) Infection in Wuhan, China. *JAMA Cardiol* 2020;**5(7)**:825-830.
- 396 3. Mehra MR, Desai SS, Kuy SR, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and
397 Mortality in Covid-19. *N Engl J Med* 2020;**382**:e102.
- 398 4. Reynolds HR, Adhikari S, Pulgarin C, Troxel AB, Iturrate E, Johnson SB, et al. Renin–Angiotensin–
399 Aldosterone System Inhibitors and Risk of Covid-19. *N Engl J Med* 2020;**382**:2441-2448.
- 400 5. Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin–Angiotensin–Aldosterone System
401 Blockers and the Risk of Covid-19. *N Engl J Med* 2020;**382**:2431-2440.
- 402 6. Bean DM, Kraljevic Z, Searle T, Bendayan R, Kevin O' G, Pickles A, et al. Angiotensin-converting
403 enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19
404 infection in a multi-site UK acute hospital trust. *Eur J Heart Fail* 2020;**22(6)**:967-974.
- 405 7. Fosbol EL, Butt JH, Østergaard L, Andersson C, Selmer C, Kragholm K, et al. Association of
406 Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19
407 Diagnosis and Mortality. *JAMA* 2020;**324(2)**:168-177.
- 408 8. Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of Use of
409 Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Testing
410 Positive for Coronavirus Disease 2019 (COVID-19). *JAMA Cardiol* 2020;**5(9)**:1020-1026.
- 411 9. Rubin SJS, Falkson SR, Degner NR, Blish CA. Safety of ACE-I and ARB medications in COVID-19:
412 A retrospective cohort study of inpatients and outpatients in California. *J Clin Transl Sci* 2020; doi:
413 10.1017/cts.2020.489.
- 414 10. Jarcho JA, Ingelfinger JR, Hamel MB, D'Agostino Sr RB, Harrington DP. Inhibitors of the Renin–
415 Angiotensin–Aldosterone System and Covid-19. *N Engl J Med* 2020;**382(25)**:2462-2464.
- 416 11. Lopes RD, Macedo AVS, de Barros E Silva PGM, Moll-Bernardes RJ, dos Santos TM, Mazzaet L,
417 al. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and
418 Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With
419 COVID-19A Randomized Clinical Trial. *JAMA* 2021;**325(3)**:254-264.
- 420 12. Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medinaet C, al. Continuation versus
421 discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a
422 prospective, randomised, open-label trial. *Lancet Respir Med* 2021;**9(3)**:275-284.

- 423 13. Bengtson CD, Montgomery RN, Nazir U, Satterwhite L, Kim MD, Bah NC, et al. An Open Label
424 Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19. *F Front*
425 *Med (Lausanne)* 2021; doi: 10.3389/fmed.2021.630209.
- 426 14. Duarte M, Pelorosso F, Nicolosi LN, Salgado MV, Vetulli H, Aquieri A, et al. Telmisartan for
427 treatment of Covid-19 patients: An open multicenter randomized clinical trial.
428 *EClinicalMedicine* 2021; doi: 10.1016/j.eclinm.2021.100962.
- 429 15. Geriak M, Haddad F, Kullar R, Greenwood KL, Habib M, Habib C, et al. Randomized Prospective
430 Open Label Study Shows No Impact on Clinical Outcome of Adding Losartan to Hospitalized
431 COVID-19 Patients with Mild Hypoxemia. *Infect Dis Ther* 2021;**10(3)**:1323-1330.
- 432 16. Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A, et al. Association Between Renin-
433 Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19A
434 Systematic Review and Meta-analysis. *JAMA Netw Open* 2021;**4(3)**:e213594.
- 435 17. Puskarich MA, Cummins NW, Ingraham NE, Wacker DA, Reilkoff RA, Driver BE, et al. A multi-
436 center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19.
437 *EClinicalMedicine* 2021; doi: 10.1016/j.eclinm.2021.100957.
- 438 18. Puskarich MA, Cummins NW, Ingraham NE, Wacker DA, Black LP, et al. A multi-center phase II
439 randomized clinical trial of losartan on symptomatic outpatients with COVID-19. *EClinicalMedicine*.
440 37. 100957. 10.1016/j.eclinm.2021.100957.
- 441 19. Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson JR, et al. Effect of
442 Hydroxychloroquine in Hospitalized Patients with Covid-19. The RECOVERY Collaborative Group.
443 *N Engl J Med* 2020;**383(21)**:2030-2040.
- 444 20. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults
445 Hospitalized with Severe Covid-19. *N Engl J Med* 2020;**382(19)**:1787-1799.
- 446 21. Wan Y, Shang J, Graham R, Baric RS, Li F. Receptor Recognition by the Novel Coronavirus from
447 Wuhan: an Analysis Based on Decade-Long Structural Studies of SARS Coronavirus. *J Virol* 2020;
448 doi: 10.1128/JVI.00127-20. Print 2020 Mar 17.
- 449 22. Letko M and Munster V, 2020. Functional assessment of cell entry and receptor usage for lineage B
450 β -coronaviruses, including 2019-nCoV. *Nat Microbiol* 2020; [https://doi.org/10.1038/s41564-020-](https://doi.org/10.1038/s41564-020-0688-y)
451 0688-y.
- 452 23. Zhou P, Yang X-L, Wang X-G, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated
453 with a new coronavirus of probable bat origin. *Nature* 2020;**579**:270–273 (2020).
- 454 24. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019
455 novel coronavirus: implications for virus origins and receptor binding. *Lancet* 2020;**395(10224)**:565-
456 574.

- 457 25. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2
458 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease
459 Inhibitor. *Cell* 2020;181(2):271-280.
- 460 26. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guanet B, et al. A crucial role of angiotensin converting
461 enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Letter. *Nat Med* 2005;11:875–879.
- 462 27. Yan Y, Liu Q, Li N, Du JC, Li X, Li C, et al. Angiotensin II receptor blocker as a novel therapy in
463 acute lung injury induced by avian influenza A H5N1 virus infection in mouse. LETTER TO THE
464 EDITOR. *Sci China Life Sci* 2015;58(2):208-11.
- 465 28. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased
466 risk for COVID-19 infection? *Lancet Respir Med* 2020; doi: 10.1016/S2213-2600(20)30116-8.
- 467 29. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–
468 Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. *N Engl J Med* 2020;
469 382:1653-1659.
- 470 30. Bozkurt B, Kovacs R, Harrington B. Joint HFSA/ACC/AHA Statement Addresses Concerns Re:
471 Using RAAS Antagonists in COVID-19. *J Card Fail* 2020; doi: 10.1016/j.cardfail.2020.04.013.
- 472 31. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of
473 Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac
474 Angiotensin-Converting Enzyme 2. *Circulation* 2005;111(20):2605-10.
- 475 32. Zheng Y, Ma Y-T, Zhang J-Y, Xie X. COVID-19 and the cardiovascular system. *Nat Rev Cardiol*
476 2020;17(5):259-260.
- 477 33. Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M, et al. Enalapril Attenuates
478 Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction
479 in Myocardial Infarcted Rat. *Hypertension* 2006;48(4):572-8.
- 480 34. Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of
481 Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II
482 Receptors. *Hypertension* 2004;43(5):970-6.
- 483 35. Soler MJ, Ye M, Wysocki J, William J, Lloveras J, Batlle D. Localization of ACE2 in the Renal
484 Vasculature: Amplification by Angiotensin II Type 1 Receptor Blockade Using Telmisartan. *Am J*
485 *Physiol Renal Physiol* 2009;296(2):F398-405.
- 486 36. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, et al. Myocardial infarction
487 increases ACE2 expression in rat and humans. *Eur Heart J* 2005;26(4):369-75.
- 488 37. Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin-
489 angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial
490 infarction: implications for future therapeutic directions. *Clin Sci (Lond)* 2012;123(11):649-58.

- 491 38. Walters TE, Kalman JM, Patel SK, Mearns M, Velkoska E, Burrell LM. Converting enzyme 2
492 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is
493 associated with atrial fibrillation and more advanced left atrial structural remodeling. *Europace*
494 2017;**19(8)**:1280-1287.
- 495 39. Ramchand J, Patel SK, Srivastava PM, Farouque O, Burrell LM. Elevated Plasma Angiotensin
496 Converting Enzyme 2 Activity Is an Independent Predictor of Major Adverse Cardiac Events in
497 Patients With Obstructive Coronary Artery Disease. *PLoS One* 2018; doi:
498 10.1371/journal.pone.0198144.
- 499 40. Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K, et al. Urinary angiotensin-
500 converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II
501 receptor blocker. *Am J Hypertens* 2015;**28(1)**:15-21.
- 502 41. Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: physiological
503 relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases.
504 *Pharmacol Res* 2017;**125(Pt A)**:21-38.
- 505 42. Chung S-C, Providencia R, Sofat R. Association between Angiotensin Blockade and Incidence of
506 Influenza in the United Kingdom. *N Engl J Med* 2020;**383(4)**:397-400.
- 507 43. Gnanenthiran SR, Borghi C, Burger D, Charchar F, Poulter NR, Schlaich MP, et al. Prospective meta-
508 analysis protocol on randomised trials of renin-angiotensin system inhibitors in patients with
509 COVID-19: an initiative of the International Society of Hypertension. *BMJ Open* 2021; doi:
510 10.1136/bmjopen-2020-043625.
- 511 44. NIH COVID-19 Treatment Guidelines. (Updated August 4, 2021. Accessed 21 September 2021.)
512 Available from <https://www.covid19treatmentguidelines.nih.gov/therapies/concomitant-medications/>.
- 513 45. de Simone G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and
514 Angiotensin Receptor Blockers. European Society of Cardiology. (13 March 2021; Accessed 1
515 October 2021.) Available from [https://www.escardio.org/Councils/Council-on-Hypertension-](https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang)
516 [-\(CHT\)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang](https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang).
- 517 46. Patel AB and Verma A. Nasal ACE2 Levels and COVID-19 in Children. *JAMA* 2020;**323(23)**:2386-
518 2387.
- 519 47. Patel AB and Verma A. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin
520 Receptor Blockers: What Is the Evidence? *JAMA* 2020;**323(18)**:1769-1770.
- 521 48. Lubel J and Garg M. Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19. *N Engl J Med*
522 2020;**382(24)**:e92.
- 523 49. Curfman G. Renin-Angiotensin-Aldosterone Inhibitors and Susceptibility to and Severity of COVID-19.
524 *JAMA* 2020;**324(2)**:177-178.

525

526 **Figure legends**

527 **Figure 1.** NCOSS over time +/- SEM. Figure on left compares losartan and combined control
528 (lopinavir/ritonavir and placebo). Figure on right compares losartan and placebo only control.
529 Comparisons of the slopes of the change for NCOSS, our primary outcome, revealed: losartan vs.
530 combined control (p=0.4), losartan vs. placebo only control (p=0.05) (trend favoring placebo), combined
531 control vs. placebo only control (p=0.267).

532

533 **Table legends**

534 **Table 1.** Baseline parameters/demographics. Losartan is compared with combined control
535 (lopinavir/ritonavir and placebo) and placebo only control. Statistically significant and 'trend'
536 comparisons are in bold.

537 **Table 2.** Efficacy. Losartan is compared with combined control (lopinavir/ritonavir and placebo) and
538 placebo only control. Statistically significant and 'trend' comparisons are in bold. Comparison of NCOSS
539 slope of the change was the study's primary efficacy outcome measurement.

540 **Table 3.** Safety. AE and SAE rates including relatedness. Losartan is compared with combined control
541 (lopinavir/ritonavir and placebo) and placebo only control. Statistically significant and 'trend'
542 comparisons are in bold. Comparison of SAE rate was the study's primary safety outcome measurement.

543

| | Treatment | Combined control | p | 95% CI | Placebo only control | p | 95% CI |
|---------------------------------------|-----------|---------------------------------|-------------|---------------------|----------------------|--------------|---------------------|
| | Losartan | Lopinavir/ritonavir and placebo | | | | | |
| N | 9 | 5 | NA | NA | 3 | NA | NA |
| Age (mean) | 63.7 | 61.8 | 0.8 | -17.0153 to 13.2153 | 56.3 | 0.4 | -27.4633 to 12.6633 |
| Male (%) | 66.7 | 60.0 | 0.9 | -0.80986 to 0.94319 | 66.7 | NA | NA |
| Enrollments spring 2020 | 11.1 | 60 | 0.1 | -1.0732 to 0.0955 | 33.3 | 0.4 | -0.7557 to 0.3112 |
| Enrollment fall 2020 - winter 2021 | 77.8 | 20 | 0.2 | -0.2486 to 1.4042 | 33.3 | 0.4 | -0.6224 to 1.5113 |
| Enrollments spring 2021 | 11.1 | 20 | 0.7 | -0.50209 to 0.32431 | 33.3 | 0.4 | -0.7557 to 0.3112 |
| Caucasian ethnicity (%) | 100 | 100 | NA | NA | 100 | NA | NA |
| NCOSS (mean) | 3.6 | 4.0 | 0.5 | -0.7192 to 1.5192 | 3.7 | 0.9 | -1.2961 to 1.4961 |
| Symptoms duration, days (mean) | 9.3 | 7.4 | 0.3 | -6.0157 to 2.315 | 6.7 | 0.3 | -7.9688 to 2.8688 |
| Comorbidities (targeted) rate (mean) | 1.0 | 2.6 | 0.02 | 0.3255 to 2.8745 | 2.7 | 0.046 | 0.0392 to 3.3608 |
| Immunocompromised (%) | 22.2 | 60 | 0.3 | -1.0311 to 0.2755 | 66.7 | 0.2 | -1.1988 to 0.3099 |
| Chronic heart disease (%) | 22.2 | 80 | 0.1 | -1.2935 to 0.1379 | 66.7 | 0.2 | -1.1988 to 0.3099 |
| Chronic lung disease (%) | 33.3 | 60 | 0.5 | -0.9823 to 0.449 | 66.7 | 0.5 | -1.1768 to 0.5101 |
| Chronic kidney disease (%) | 0 | 0 | NA | NA | 0 | NA | NA |
| Chronic liver disease (%) | 0 | 0 | NA | NA | 0 | NA | NA |
| Diabetes (%) | 22.2 | 25 | 0.9 | -0.48384 to 0.52828 | 33.3 | 0.7 | -0.7644 to 0.5422 |
| Extreme obesity (%) | 0 | 50 | 0.03 | -0.962 to -0.038 | 50 | 0.03 | -0.962 to -0.038 |
| Charlson Score (mean) | 2.5 | 4.5 | 0.08 | -0.3196 to 4.3196 | 3.7 | 0.3 | -1.1366 to 3.5366 |
| qSOFA (mean) | 0.33 | 0.6 | 0.4 | -0.3585 to 0.8985 | 0.3 | 1 | -0.7680 to 0.7680 |
| BMI (mean) | 31.0 | 31.8 | 0.4 | -4.2764 to 9.2764 | 35.1 | 0.2 | -2.3076 to 10.5076 |
| Creatinine (mean) | 0.7 | 0.9 | 0.4 | -0.2508 to 0.5708 | 0.7 | 0.9 | -0.2127 to 0.2327 |
| Chest x-ray opacities (%) | 88.9 | 100 | 0.9 | -1.1646 to 0.9423 | 100 | 0.9 | -1.3621 to 1.1399 |
| Pneumonia severity index (PSI) (mean) | 54.9 | 59.3 | 0.5 | -41.3071 to 50.1071 | 60 | 0.8 | -40.4537 to 21.2537 |
| Treatment days (mean) | 9.6 | 13.3 | 0.3 | -3.5545 to 10.8545 | 13 | 0.4 | -5.1086 to 11.9086 |
| Treatment with corticosteroids (%) | 88.9 | 40 | 0.3 | -0.7949 to 0.2172 | 60 | 0.7 | -0.9706 to 1.415 |

544

545 **Table 1.**

546

| | Treatment | | p | 95% CI | Placebo only control | | p | 95% CI |
|-------------------------------------|-----------|---|-----|---------------------|----------------------|-------------|--------------------|--------|
| | Losartan | Combined control Lopinavir/ritonavir and placebo | | | Placebo | | | |
| NCOSS slope of the change | 0.0037 | 0.0209 | 0.4 | | 0.0527 | 0.05 | | |
| NCOSS change day 60 | 0.7 | 1.8 | 0.6 | -2.8175 to 5.0175 | 3.3 | 0.2 | -1.6690 to 6.8690 | |
| Mortality, 60 days (%) | 44.4 | 20.0 | 0.9 | -0.67123 to 0.76012 | 0 | 0.2 | -0.3099 to 1.1988 | |
| First negative PCR, days (mean) | 6.5 | 10.5 | 0.7 | -12.3243 to 16.3243 | 3 | NA | NA | |
| Hospital LOS, days (mean) | 16.4 | 7.0 | 0.2 | -25.2922 to 6.4922 | 6.3 | 0.3 | -28.8728 to 8.6728 | |
| Mechanical ventilation, days (mean) | 8.5 | 0 | NA | NA | 0 | NA | NA | |

547

548 **Table 2.**

549

| | Losartan | | | | | Control (placebo or lopinavir/ritonavir) | | | | | p | 95% CI | Control (placebo) | | | | | p | 95% CI |
|---|----------|------------|----------|----------|------|--|------------|----------|----------|-----|------|-------------------|-------------------|------------|----------|----------|-----|----|--------|
| | Total | Definitely | Probably | Possibly | Not | Total | Definitely | Probably | Possibly | Not | | | Total | Definitely | Probably | Possibly | Not | | |
| AEs/subject (mean) | 3.9 | 0 | 0 | 1.0 | 2.9 | 1.0 | 0 | 0 | 1.0 | 0 | 0.3 | -8.3414 to 2.5414 | 0 | 0 | 0 | 0 | 0 | NA | NA |
| SAEs/subject (mean) | 2.0 | 0 | 0 | 0.4 | 1.6 | 0.60 | 0 | 0 | 0.6 | 0 | 0.3 | -4.3144 to 1.5144 | 0 | 0 | 0 | 0 | 0 | NA | NA |
| AKI AEs/subject (mean) | 0.22 | 0 | 0 | 0.11 | 0.11 | 0.20 | 0 | 0 | 0.2 | 0 | 0.95 | -0.7560 to 0.7160 | 0 | 0 | 0 | 0 | 0 | NA | NA |
| AKI SAEs/subject (mean) | 0.11 | 0 | 0 | 0.00 | 0.11 | 0.20 | 0 | 0 | 0.2 | 0 | 0.5 | -0.5160 to 0.9560 | 0 | 0 | 0 | 0 | 0 | NA | NA |
| Hypotension AEs/subject (mean) | 0.33 | 0 | 0 | 0.22 | 0.11 | 0 | 0 | 0 | 0 | 0 | NA | NA | 0 | 0 | 0 | 0 | 0 | NA | NA |
| Hypotension SAEs/subject (mean) | 0.22 | 0 | 0 | 0.11 | 0.11 | 0 | 0 | 0 | 0 | 0 | NA | NA | 0 | 0 | 0 | 0 | 0 | NA | NA |
| Hyperkalemia AEs/subject (mean) | 0.11 | 0 | 0 | 0.11 | 0 | 0 | 0 | 0 | 0 | 0 | NA | NA | 0 | 0 | 0 | 0 | 0 | NA | NA |
| Hyperkalemia SAEs/subject (mean) | 0.00 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | NA | NA | 0 | 0 | 0 | 0 | 0 | NA | NA |
| Respiratory failure/COVID-19 PNA AEs rate (mean) | 0.67 | 0 | 0 | 0.33 | 0.33 | 0.20 | 0 | 0 | 0.2 | 0 | 0.2 | -1.2420 to 0.3020 | 0 | 0 | 0 | 0 | 0 | NA | NA |
| Respiratory failure/COVID-19 PNA SAEs rate (mean) | 0.67 | 0 | 0 | 0.33 | 0.33 | 0.20 | 0 | 0 | 0.2 | 0 | 0.2 | -1.2420 to 0.3020 | 0 | 0 | 0 | 0 | 0 | NA | NA |

550

551 **Table 3.**

552





Figure 1